{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:16Z","timestamp":1792787956901,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSL Behring"},{"name":"Grifols","id":[{"id":"https:\/\/ror.org\/02ed64f32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03796-y","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:17:17Z","timestamp":1784621837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Alpha-1 Antitrypsin Deficiency testing across Europe to ensure diagnostic accuracy: an EARCO multicentre project"],"prefix":"10.1186","volume":"27","author":[{"given":"Joanna","family":"Chorostowska-Wynimko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pelc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Balduyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s P","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Gerard","family":"McElvaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Fran\u00e7oise","family":"Odou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Seixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Orriols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Zerimech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Guido","family":"Corsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wencker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ferrarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"15","key":"3796_CR1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMra1910234","volume":"382","author":"P Strnad","year":"2020","unstructured":"Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443\u201355.","journal-title":"N Engl J Med"},{"key":"3796_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/TACG.S257511","volume":"14","author":"S Seixas","year":"2021","unstructured":"Seixas S, Marques PI. Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. Appl Clin Genet. 2021;14:173\u201394.","journal-title":"Appl Clin Genet"},{"issue":"1","key":"3796_CR3","doi-asserted-by":"publisher","first-page":"16051","DOI":"10.1038\/nrdp.2016.51","volume":"2","author":"CM Greene","year":"2016","unstructured":"Greene CM, Marciniak SJ, Teckman J, et al. \u03b11-antitrypsin deficiency. Nat Rev Dis Primers. 2016;2(1):16051.","journal-title":"Nat Rev Dis Primers"},{"issue":"2S","key":"3796_CR4","first-page":"33","volume":"12","author":"KE Foil","year":"2021","unstructured":"Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis. 2021;12(2S):33\u201348.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"3796_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT den Dunnen","year":"2016","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564\u20139.","journal-title":"Hum Mutat"},{"issue":"1","key":"3796_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-024-03069-1","volume":"19","author":"I Ferrarotti","year":"2024","unstructured":"Ferrarotti I, Wencker M, Chorostowska-Wynimko J. Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review. Orphanet J Rare Dis. 2024;19(1):82.","journal-title":"Orphanet J Rare Dis"},{"key":"3796_CR7","doi-asserted-by":"publisher","first-page":"9859","DOI":"10.3390\/ijms23179859","volume":"23","author":"V Barzon","year":"2022","unstructured":"Barzon V, Ottaviani S, Balderacchi AM, et al. Improving the laboratory diagnosis of M-like variants related to alpha1-antitrypsin deficiency. Int J Mol Sci. 2022;23:9859.","journal-title":"Int J Mol Sci"},{"key":"3796_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-0716-3605-3_6","volume-title":"Alpha-1 Antitrypsin: Methods and Protocols","author":"V Barzon","year":"2024","unstructured":"Barzon V, Ferrarotti I, Ottaviani S. Sanger and next-generation sequencing of AAT. In: Bristow CL, editor. Alpha-1 Antitrypsin: Methods and Protocols. New York, NY: Springer US; 2024. pp. 57\u201367."},{"issue":"9","key":"3796_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/humu.23562","volume":"39","author":"E Giacopuzzi","year":"2018","unstructured":"Giacopuzzi E, Laffranchi M, Berardelli R, et al. Real-world clinical applicability of pathogenicity predictors assessed on SERPINA1 mutations in alpha-1-antitrypsin deficiency. Hum Mutat. 2018;39(9):1203\u201313.","journal-title":"Hum Mutat"},{"issue":"1","key":"3796_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12881-019-0852-5","volume":"20","author":"F Kueppers","year":"2019","unstructured":"Kueppers F, Andrake MD, Xu Q, et al. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having alpha 1 antitrypsin deficiency. BMC Med Genet. 2019;20(1):125.","journal-title":"BMC Med Genet"},{"issue":"3","key":"3796_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/genes15030340","volume":"15","author":"J Mr\u00f3z","year":"2024","unstructured":"Mr\u00f3z J, Pelc M, Mitusi\u0144ska K, et al. Computational tools to assist in analyzing effects of the SERPINA1 gene variation on alpha-1 antitrypsin (AAT). Genes. 2024;15(3):340.","journal-title":"Genes"},{"issue":"Suppl 1","key":"3796_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/15412555.2013.763782","volume":"10","author":"JK Stoller","year":"2013","unstructured":"Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD. 2013;10(Suppl 1):26\u201334.","journal-title":"COPD"},{"issue":"1","key":"3796_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-020-01352-5","volume":"15","author":"M Brantly","year":"2020","unstructured":"Brantly M, Campos M, Davis AM, et al. Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet J Rare Dis. 2020;15(1):96.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3796_CR14","doi-asserted-by":"publisher","first-page":"e0135316","DOI":"10.1371\/journal.pone.0135316","volume":"10","author":"I Ferrarotti","year":"2015","unstructured":"Ferrarotti I, Poplawska-Wisniewska B, Trevisan MT, et al. How can we improve the detection of alpha1-antitrypsin deficiency? PLoS ONE. 2015;10(8):e0135316.","journal-title":"PLoS ONE"},{"key":"3796_CR15","unstructured":"Orphanet. Alpha-1-antitrypsin deficiency. 2024 https:\/\/www.orpha.net\/en\/disease\/detail\/60. Date last accessed: July 31, 2025."},{"issue":"2","key":"3796_CR16","doi-asserted-by":"publisher","first-page":"1900138","DOI":"10.1183\/13993003.00138-2019","volume":"53","author":"M Miravitlles","year":"2019","unstructured":"Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS clinical research collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J. 2019;53(2):1900138.","journal-title":"Eur Respir J"},{"issue":"Suppl C","key":"3796_CR17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/rmed.2000.0852","volume":"94","author":"M Miravitlles","year":"2000","unstructured":"Miravitlles M. Alpha1-antitrypsin deficiency: epidemiology and prevalence. Respir Med. 2000;94(Suppl C):S12\u20135.","journal-title":"Respir Med"},{"key":"3796_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-0716-3605-3_12","volume":"2750","author":"C Marin-Hinojosa","year":"2024","unstructured":"Marin-Hinojosa C, Fatela-Cantillo D, Lopez-Campos JL. Measuring of alpha-1 antitrypsin concentration by nephelometry or turbidimetry. Methods Mol Biol. 2024;2750:123\u201333.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"3796_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1515\/CCLM.2008.036","volume":"46","author":"F Zerimech","year":"2008","unstructured":"Zerimech F, Hennache G, Bellon F, et al. Evaluation of a new Sebia isoelectrofocusing kit for \u03b11-antitrypsin phenotyping with the Hydrasys\u00ae System. Clin Chem Lab Med. 2008;46(2):260\u20133.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"3796_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2500\/aap.2017.38.4031","volume":"38","author":"F Kueppers","year":"2017","unstructured":"Kueppers F, Sanders C. State-of-the-art testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38(2):108\u201314.","journal-title":"Allergy Asthma Proc"},{"key":"3796_CR21","volume-title":"\u03b11-Antitrypsin deficiency (ERS monograph)","author":"I Ferrarotti","year":"2019","unstructured":"Ferrarotti I, Ottaviani S. Laboratory diagnosis of AATD. In: Strnad P, Brantly ML, Bals R, editors. \u03b11-Antitrypsin deficiency (ERS monograph). Sheffield: European Respiratory Society; 2019."},{"issue":"12","key":"3796_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S2213-2600(19)30141-9","volume":"7","author":"AN Franciosi","year":"2019","unstructured":"Franciosi AN, Carroll TP, McElvaney NG. Pitfalls and caveats in \u03b11-antitrypsin deficiency testing: a guide for clinicians. Lancet Respir Med. 2019;7(12):1059\u201367.","journal-title":"Lancet Respir Med"},{"key":"3796_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-94-007-4549-0_5","volume":"756","author":"R Struniawski","year":"2013","unstructured":"Struniawski R, Szpechcinski A, Poplawska B, et al. Rapid DNA extraction protocol for detection of alpha-1 antitrypsin deficiency from dried blood spots by real-time PCR. Adv Exp Med Biol. 2013;756:29\u201337.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"3796_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/01.pas.0000178221.44474.b3","volume":"14","author":"G Orr\u00f9","year":"2005","unstructured":"Orr\u00f9 G, Faa G, Pillai S, et al. Rapid PCR real-time genotyping of M-Malton alpha1-antitrypsin deficiency alleles by molecular beacons. Diagn Mol Pathol. 2005;14(4):237\u201342.","journal-title":"Diagn Mol Pathol"},{"key":"3796_CR25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2147\/COPD.S224221","volume":"14","author":"M Veith","year":"2019","unstructured":"Veith M, Klemmer A, Anton I, et al. Diagnosing alpha-1-antitrypsin deficiency using a PCR\/luminescence-based technology. Int J Chron Obstruct Pulmon Dis. 2019;14:2535\u201342.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"3796_CR26","doi-asserted-by":"publisher","first-page":"e23279","DOI":"10.1002\/jcla.23279","volume":"34","author":"S Ottaviani","year":"2020","unstructured":"Ottaviani S, Barzon V, Buxens A, et al. Molecular diagnosis of alpha1-antitrypsin deficiency: a new method based on Luminex technology. J Clin Lab Anal. 2020;34(7):e23279.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"3796_CR27","doi-asserted-by":"publisher","first-page":"2000958","DOI":"10.1183\/13993003.00958-2020","volume":"56","author":"N Gupta","year":"2020","unstructured":"Gupta N, Gaudreault N, Th\u00e9riault S, et al. Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD. Eur Respir J. 2020;56(4):2000958.","journal-title":"Eur Respir J"},{"issue":"1","key":"3796_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12687-010-0009-x","volume":"1","author":"RJ Hastings","year":"2010","unstructured":"Hastings RJ, Howell RT. The importance and value of EQA for diagnostic genetic laboratories. J Community Genet. 2010;1(1):11\u20137.","journal-title":"J Community Genet"},{"issue":"15","key":"3796_CR29","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.3390\/cancers14153686","volume":"14","author":"N Laudus","year":"2022","unstructured":"Laudus N, Nijs L, Nauwelaers I, et al. The significance of external quality assessment schemes for molecular testing in clinical laboratories. Cancers. 2022;14(15):3686.","journal-title":"Cancers"},{"key":"3796_CR30","doi-asserted-by":"crossref","unstructured":"Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. John Wiley & Sons, Inc.; 2003.","DOI":"10.1002\/0471445428"},{"issue":"5","key":"3796_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.trsl.2007.08.001","volume":"150","author":"I Ferrarotti","year":"2007","unstructured":"Ferrarotti I, Scabini R, Campo I, et al. Laboratory diagnosis of alpha1-antitrypsin deficiency. Transl Res. 2007;150(5):267\u201374.","journal-title":"Transl Res"},{"issue":"8","key":"3796_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/thoraxjnl-2011-201321","volume":"67","author":"I Ferrarotti","year":"2012","unstructured":"Ferrarotti I, Thun GA, Zorzetto M, et al. Serum levels and genotype distribution of \u03b11-antitrypsin in the general population. Thorax. 2012;67(8):669\u201374.","journal-title":"Thorax"},{"key":"3796_CR33","unstructured":"Stoller J, Hupertz V, Aboussouan L, Alpha-1 Antitrypsin Deficiency. 2006 Oct 27 [Updated 2023 Jun 1] In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews\u00ae [Internet], Seattle (WA), USA: University of Washington, Seattle; 1993\u20132024. Avaialble from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1519\/. Date last accessed: July 31, 2025."},{"issue":"3","key":"3796_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/00313029600169074","volume":"28","author":"L Cook","year":"1996","unstructured":"Cook L, Burdon JG, Brenton S, et al. Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase. Pathology. 1996;28(3):242\u20137.","journal-title":"Pathology"},{"key":"3796_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2466-14-132","volume":"14","author":"NJ Sinden","year":"2014","unstructured":"Sinden NJ, Koura F, Stockley RA. The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote. BMC Pulm Med. 2014;14:132.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"3796_CR36","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.2203025","volume":"166","author":"F Rodriguez","year":"2002","unstructured":"Rodriguez F, Jard\u00ed R, Costa X, et al. Rapid screening for alpha1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am J Respir Crit Care Med. 2002;166(6):814\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3796_CR37","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","volume":"50","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in \u03b11-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610.","journal-title":"Eur Respir J"},{"issue":"1","key":"3796_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/15412555.2017.1401600","volume":"15","author":"CL Sanders","year":"2018","unstructured":"Sanders CL, Ponte A, Kueppers F. The effects of inflammation on alpha 1 antitrypsin levels in a national screening cohort. COPD. 2018;15(1):10\u20136.","journal-title":"COPD"},{"issue":"5","key":"3796_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"1","key":"3796_CR40","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1002\/cphg.93","volume":"103","author":"SM Harrison","year":"2019","unstructured":"Harrison SM, Biesecker LG, Rehm HL. Overview of specifications to the ACMG\/AMP variant interpretation guidelines. Curr Protoc Hum Genet. 2019;103(1):e93.","journal-title":"Curr Protoc Hum Genet"},{"issue":"6","key":"3796_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/humu.22975","volume":"37","author":"V Tack","year":"2016","unstructured":"Tack V, Deans ZC, Wolstenholme N, et al. What\u2019s in a name? A coordinated approach toward the correct use of a uniform nomenclature to improve patient reports and databases. Hum Mutat. 2016;37(6):570\u20135.","journal-title":"Hum Mutat"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03796-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03796-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03796-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:41Z","timestamp":1792086281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03796-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03796-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A protocol for this research was approved by the relevant institutional review boards for the two reference laboratories involved in this study. This research was conducted in accordance with the Declaration of Helsinki. Patients from Labs A and B approved by written informed consent to the use of anonymised materials for research. No additional blood sampling was performed to obtain material for this project; only unused diagnostic samples.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research manuscript does not include data from patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.C.-W. has received grants from Astra Zeneca and Chiesi, consulting fees from AstraZeneca, Chiesi, CSL Behring, Grifols, MSD, and Sanofi, honoraria from Astra Zeneca, Chiesi, CSL Behring, Grifols, Johnson & Johnson, MSD, Pfizer, and Sanofi, meeting support from Amgen and Astra Zeneca, has participated in data safety monitoring\/advisory boards for Chiesi, MSD, CSL Behring, and Grifols, received medical writing support from CSL Behring, and has leadership roles in European Respiratory Society, Polish Respiratory Society, International Respiratory Coalition, Polish Coalition for Respiratory Disorders, Polish Coalition for Treatment of Asthma, and Polish Foundation for Patients with Alpha-1 Antitrypsin Deficiency. S.O. declares no conflicts of interest. M.P. declares no conflicts of interest. M.B. declares no conflicts of interest. T.P.C. declares no conflicts of interest. T.G. has received grants from Grifols and fees from CSL-Behring, Grifols and Kamada. N.G.M. has received research grants and honoraria from Grifols, has received consulting fees from CSL Behring and Vertex, and has participated in advisory boards for CSL Behring and Vertex. M.M. has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Glenmark Pharmaceuticals, Menarini, Kamada, Takeda, Zambon, Tabuk Pharmaceuticals, CSL Behring, Specialty Therapeutics, Sanofi\/Regeneron, Grifols, and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, BEAM Therapeutics, GondolaBio, Chiesi, GlaxoSmithKline, CSL Behring, Ferrer, Korrobio, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi\/Regeneron, Zambon, Zentiva, and Grifols, and research grants from Grifols. F.R.-F. declares no conflicts of interest. M.-F.O. declares no conflicts of interest. A.R. declares no conflicts of interest. S.S. has received speaker and consulting fees from CSL Behring, and grants from FUCAP (FUNDACI\u00d3 CATALANA DE PNEUMOLOGIA). G.O. declares no conflicts of interest. M.V. has received grants from Grifols. F.Z. declares no conflicts of interest. A.G.C. has received speaker fees and honoraria for participation on advisory board from CSL Behring, and honoraria for manuscript writing from Grifols. M.C.M. declares no conflicts of interest. M.W. reports consultancy fees from CSL Behring. I.F. reports consulting fees from Grifols, and unrestrictive grants from Grifols and CSL Behring.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"405"}}